Retatrutide UK: what it is, how it works, and current status
Retatrutide is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, and its phase 3 TRIUMPH trials have reported the strongest weight-loss results of any drug in this class so far — up to 30.3% average weight loss, plus measured benefits for knee pain, liver fat and cardiovascular risk markers. It is not licensed in the UK yet. Here is what the evidence actually shows, and what is already available today if you would rather not wait.
How retatrutide works
Most GLP-1 medicines target one or two receptors. Retatrutide targets three at once, which is the whole reason it is generating this level of trial interest.
How the three main options compare
Semaglutide and tirzepatide are already licensed and prescribed in the UK. Retatrutide is the newest and, on trial data so far, the strongest — but it is also the least proven in real-world use. See the full head-to-head comparison →
| Medicine | Receptors targeted | Best reported weight loss | UK status |
|---|---|---|---|
| Semaglutide Wegovy / Ozempic / Rybelsus | GLP-1 only | Around 15% (STEP trials) | Licensed & available — deepest cardiovascular outcomes evidence (SELECT trial) |
| Tirzepatide Mounjaro | GLP-1 + GIP | Around 21% (SURMOUNT trials) | Licensed & available |
| Retatrutide | GLP-1 + GIP + glucagon | Up to 30.3% (TRIUMPH-1, phase 3) | Not licensed anywhere yet — phase 3, FDA filing expected early 2027 |
What's actually available in the UK today
Retatrutide is still in trials, with realistic UK licensing not expected before late 2027 to mid-2028. If you would rather not wait, both of retatrutide's licensed relatives are already available through regulated UK providers.
TRIUMPH in one view
TRIUMPH-1 is the pure obesity story: adults with obesity or overweight and no other qualifying condition. TRIUMPH-2 and TRIUMPH-3 add comorbidity populations — type 2 diabetes and established cardiovascular disease — which matters because it shows retatrutide's effect is not limited to a narrow trial population. TRIUMPH-4 (obesity plus knee osteoarthritis) was the first of the four to report.
TRIUMPH-1 in plain English
TRIUMPH-1 asks whether retatrutide can deliver meaningful weight loss in adults with obesity who do not have diabetes. At 80 weeks, the 12mg dose produced 28.3% average weight loss; participants with a starting BMI of 35 or higher who continued treatment reached up to 30.3% at 104 weeks.
TRIUMPH-2 and TRIUMPH-3 in plain English
TRIUMPH-2 (type 2 diabetes plus obesity or overweight) and TRIUMPH-3 (obesity plus established cardiovascular disease) both met their primary endpoints in July 2026, giving retatrutide a diabetes evidence lane and a cardiovascular-risk evidence lane, not just an obesity-only result.
| Evidence item | Population and design | Main signal | UK meaning |
|---|---|---|---|
| TRIUMPH-4 Dec 2025 | Adults with obesity or overweight and knee osteoarthritis; phase 3. | Up to 28.7% average weight loss (average 32.3kg) at 68 weeks, plus reported knee-pain relief and improved cardiovascular risk markers (non-HDL cholesterol, systolic blood pressure). | First successful TRIUMPH readout. Trial-level efficacy evidence only, not a UK licensing event. |
| TRIUMPH-1 May 2026 | Adults with obesity or overweight, no diabetes; phase 3, 80 and 104-week endpoints. | 28.3% average weight loss at 80 weeks (12mg dose); up to 30.3% at 104 weeks in BMI≥35 continuers. | The single strongest headline number in the programme so far. Still phase 3 data, not a submitted or reviewed regulatory package. |
| TRIUMPH-2 Jul 2026 | Adults with type 2 diabetes and obesity or overweight; n=1,152; 80-week endpoint. | Mean weight change −20.8% (12mg) vs −4.0% placebo; HbA1c reduction of 1.4–1.6 percentage points vs 0.2pp placebo. | Extends the evidence base beyond a pure weight-loss population to a diabetes-relevant one. |
| TRIUMPH-3 Jul 2026 | Adults with obesity (BMI≥35) and established cardiovascular disease; n=1,949; 80-week endpoint. | Weight change up to −22.6% (12mg) vs −3.2% placebo, plus improvements in triglycerides, blood pressure and inflammatory markers. | Adds a cardiovascular-risk population to the evidence base. Trial-level safety and efficacy signal, not a UK safety alert or approval. |
Benefits beyond weight loss
Because retatrutide adds the glucagon pathway on top of GLP-1 and GIP, trial investigators have measured effects beyond the scale — these are the headline findings so far, each from a specific TRIUMPH sub-analysis.
UK regulatory footprint so far
Retatrutide has no marketing authorisation anywhere in the world, including the UK. Eli Lilly has indicated a planned FDA submission in Q1 2027; realistic estimates put MHRA marketing authorisation at late 2027 to mid-2028, with NHS access through NICE appraisal likely later still.
The only lawful UK access route
The only way anyone in the UK lawfully receives retatrutide today is as a participant in an authorised clinical trial.
What "checked" means on this page
This page is reviewed against FDA, MHRA, GOV.UK, NICE and EMA sources, not against seller websites. A dated pre-launch tracker for retatrutide runs separately and does not feed prices or providers into this page or into any comparison table on this network.
Legal status and the enforcement record
Evidence limits
These trials support the statement that retatrutide is currently reporting the strongest weight-loss data in the GLP-1 class. They do not support shortcuts such as "retatrutide is basically approved" or "the trial results mean it's safe to buy now."